Cell therapy
-
Johnson & Johnson Strikes Deal with US Government to Expand Medicine Access and Reduce Costs for Americans, Fulfilling Manufacturing and Innovation Commitments
Johnson & Johnson has partnered with the U.S. administration to lower drug prices and expand its domestic footprint. This agreement will provide millions of Americans with access to discounted pharmaceuticals and exempt these medicines from U.S. tariffs. The company is reinforcing its $55 billion U.S. investment, with plans for two new advanced manufacturing facilities for cell therapies and biologics, creating thousands of jobs and demonstrating a commitment to U.S.-based production and innovation.
-
Ryoncil® Net Revenues Increase 69% in Second Quarter Post-Launch
Mesoblast (MESO) reported Q1 FY2026 results with cell therapy revenue of $20.6M, up from $12.9M sequentially. Ryoncil gross sales rose 66% to $21.9M; net sales increased 69% to $19.1M after adjustments. A permanent Ryoncil J-code (J3402) became active 10/1/25 and federal Medicaid coverage is mandatory from 7/1/25. The company held $145M cash and secured convertible note agreements for up to $50M (subject to approval). They onboarded 40 transplant centers with coverage over 260M lives.
